Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
Intervalo de ano de publicação
2.
East Mediterr Health J ; 26(1): 102-109, 2020 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-32043552

RESUMO

BACKGROUND: The World Health Organization (WHO) MPOWER measures are a set of highly effective tobacco control measures drawn from the WHO Framework Convention on Tobacco Control (FCTC), designed to help countries reduce the prevalence of tobacco use. The WHO Report on the Global Tobacco Epidemic is published biennially to monitor global implementation of these measures. AIMS: This review aimed to critically assess the status of MPOWER implementation in the Eastern Mediterranean Region. METHODS: Data were collected for WHO Reports on the Global Tobacco Epidemic, focusing on the most recent 2019 edition. Regional population coverage figures were calculated using this data and population figures for the countries of the Region. RESULTS: Between 2007 and 2018, for any MPOWER measure, there were 29 cases of countries progressing to the highest level of achievement; 23 cases of countries progressing to the intermediate levels from the lowest level; 12 cases of countries falling from the highest level; and 18 cases of countries falling to the lowest level. 57.7% of people are covered at the highest level for the monitoring measure; 63.7% for the smoke-free policies measure; 6.7% for the cessation measure; 60.7% for the health warnings measure; 37.4% for the mass media measure; 29.4% for the advertising bans measure; and 16.1% for the taxation measure. CONCLUSIONS: Countries must work comprehensively to improve tobacco control. Regional priorities should include lifting more people out of lowest level coverage for the health warnings and mass media measures, increasing taxation on tobacco products and improving access to cessation services.


Assuntos
Prevenção do Hábito de Fumar/organização & administração , Uso de Tabaco/epidemiologia , Uso de Tabaco/prevenção & controle , África do Norte/epidemiologia , Estudos Transversais , Saúde Global , Educação em Saúde/organização & administração , Política de Saúde , Humanos , Marketing/legislação & jurisprudência , Oriente Médio/epidemiologia , Vigilância de Evento Sentinela , Abandono do Hábito de Fumar/métodos , Prevenção do Hábito de Fumar/economia , Prevenção do Hábito de Fumar/legislação & jurisprudência , Impostos/economia , Impostos/legislação & jurisprudência , Poluição por Fumaça de Tabaco/prevenção & controle , Organização Mundial da Saúde
3.
East Mediterr Health J ; 26(1): 110-115, 2020 Jan 30.
Artigo em Inglês | MEDLINE | ID: mdl-32043553

RESUMO

The report aimed to review and assess the status of tobacco cessation services in the Eastern Mediterranean Region (EMR). Nearly 70% of people in the Region have legal access to nicotine-replacement therapy but for 77% of these people the costs of the treatment are not covered. Bupropion and Varenicline are legally available in 10 and 11 EMR countries respectively. Just under 50% of people in the Region have access to at least some cessation support in primary health care facilities. Around 32% of people have access to a national toll-free quit line. Costs for cessation services are fully covered in few EMR countries; however, cessation services in the Region must be improved. Member States should aim to increase the availability of, and financial support for, cessation treatments and support, which should be prioritized in primary health care facilities.


Assuntos
Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Agentes de Cessação do Hábito de Fumar/uso terapêutico , Abandono do Hábito de Fumar/métodos , África do Norte , Bupropiona/provisão & distribuição , Bupropiona/uso terapêutico , Humanos , Oriente Médio , Atenção Primária à Saúde/estatística & dados numéricos , Agentes de Cessação do Hábito de Fumar/economia , Agentes de Cessação do Hábito de Fumar/provisão & distribuição , Vareniclina/provisão & distribuição , Vareniclina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA